Daily Debrief: What Happened Today (Apr 13)

Stories you might have missed

Temasek CEO Dilhan Pillay to chair Vertex as FY2025 profit tops US$100 million

[SINGAPORE] Dilhan Pillay, executive director and CEO of Temasek, will succeed Teo Ming Kian as the chairman of Vertex Venture Holdings from Apr 15, the venture capital firm said in a media release on Friday (Apr 10).

Keppel warns of ‘second-order’ shocks from prolonged Middle East conflict

[SINGAPORE] Keppel has warned that while its direct exposure to the Middle East remains limited, an escalation in regional conflict could trigger significant “second-order” effects on global energy prices and the international economy.

Competition watchdog greenlights GlobalFoundries’ acquisition of Advanced Micro Foundry

[SINGAPORE] The Competition and Consumer Commission of Singapore (CCS) has cleared the completed acquisition of Singapore’s Advanced Micro Foundry (AMF) by New York-headquartered semiconductor company GlobalFoundries, it announced on Monday (Apr 13).

‘A painful March’: UOBKH’s Alpha Picks underperform STI as Iran war triggers sell-offs

[SINGAPORE] UOB Kay Hian’s (UOBKH) Alpha Picks portfolio underperformed the Straits Times Index (STI) by 6.4 percentage points on an equal-weighted basis in March, as jitters over the Iran war triggered sell-offs.

BlueSg’s revamped car-sharing service Flexar to begin public beta testing

[SINGAPORE] Electric car-sharing company BlueSG will begin beta-phase testing for Flexar, its new point-to-point car-sharing service, on Wednesday (Apr 15), Flexar said on Monday. 

Singapore-listed iX Biopharma bets big on non-opioid pain relief

[SINGAPORE] It took semaglutide (an anti-diabetic prescription drug that is gaining traction as an anti-obesity medication) to convince Wall Street that an overlooked drug class could become a hundred-billion-dollar market. Now, a handful of companies are betting that non-opioid pain relief is next – and Singapore’s iX Biopharma thinks it has the edge.